TREOS Bio, Charité Berlin, and Junshi Biosciences to Launch Pivotal Ph 2 Trial of PolyPEPI1018, toripalimab, and SoC combo in Refractory MSS CRC September 3, 2025
HERTHENA-Breast04 Ph 3 Trial of Patritumab Deruxtecan Initiated for Metastatic HR+ve, HER2-neg Breast Cancer Previously Treated with Endocrine Therapy September 3, 2025
HERNEXEOS® approved in China for previously treated patients with HER2-mutant advanced NSCLC September 3, 2025
CHARM Therapeutics raises $80M in Series B financing to advance development of menin inhibitor for AML September 3, 2025
Clinical development of ZW171 to be discontinued in gynecological, thoracic, and digestive system cancers September 3, 2025
Positive Topline Results for Sonrotoclax in R/R MCL Announced; primary endpoint of ORR met September 3, 2025
FDA granted Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for Patients with KRAS G12C-Mutated Cancers September 3, 2025
Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US September 3, 2025
Accro Bioscience and Fosun Pharma Announce Exclusive License Agreement for AC-201 in Greater China September 3, 2025
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer September 3, 2025
First Patient Dosed in Expansion Cohorts of Ph 1/2 SOLARA Trial of BH-30643 in Advanced EGFRm NSCLC September 3, 2025
First cohort in Ph 1 trial of 177Lu-AKIR001 completed in patients with solid tumors September 3, 2025
SAKK 66/17 Ph 1b/2a Clinical Trial of IP-001 for Treatment of Solid Tumors Completed September 3, 2025
Initial Data Shows 100% Disease Control in all 5 Recurrent GBM patients and Near CR in 2, Treated With ANKTIVA® + Optune Gio® Device September 3, 2025
Ongoing Ph 1 APOLLO study of MT-601 in patients with relapsed B cell lymphoma showed 66% ORR and 50% CR in NHL patients September 3, 2025
